Antibody-drug conjugate Korea MFDS approval & launch

1What does this company do?

Republic of Korea affiliate of a global oncology sponsor executing first local MFDS marketing authorization and commercial launch handoff.

2Where is the product on its way to patients?

HER2-directed antibody-drug conjugate (ADC) at Korea MFDS initial marketing authorization.

1. 1Discovery & Lead Selection
2. 2IND-Enabling Nonclinical
3. 3Clinical Development (IND / CTA)
4. 4Registration & Dossier Review
5. 5Approval & Launch Readiness
   • The product is here
6. 6Commercial Lifecycle & GMP

3What is happening right now?

First Korea MFDS approval has landed; commercial launch handoff and repository lock occur tomorrow morning.

4Tasks

7 tasks in the 81-task Biopharma Bench V0.2 suite, graded against expert rubric criteria.

See the leaderboard →

Sealed partner records & open showcases

This environment is reconstructed from a confidential drug or device program, so its records, tasks, and rubrics remain sealed.

To inspect complete workspaces, candidate deliverables, trajectories, and rubric criteria end to end, open the two public companion showcases:

Havenor Therapeutics (synthetic sterile-injectables CMC/MSAT) →
Broad Institute (public FDA CDER IND 167326 record) →

← Back to all company environments